EUCTR2009-018091-34-GR进行中（未招募）不适用
A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in ß-thalassemia patients with severe cardiac iron overload - DFX Autonomy
ovartis (Hellas) S.A.C.I0 个研究点目标入组 52 人开始时间: 2010年11月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients with ß-thalassemia major, at least 18 years old, having given written consent to participate in the study.
- •Cardiac MRI T2* value ranging from 5 to <10 ms.
- •LVEF = 56 % as determined by CMR.
- •Patients with LIC > 10 mg Fe/g dw will be included in the protocol. Study will evaluate the first 10 patients at 6 months, and if no safety signals are present, patients with LIC>7 mg Fe/g dw will be allowed to be included.
- •Prior iron chelation treatment with DFO, DFP, DFX or combination DFO-DFP.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with symptoms of cardiac dysfunction symptoms
- •Patients with cardiac T2* MRI < 5 or > 10 ms.
- •Patients not responding to intensive iron chelation therapy regimens such i.v DFO 24 hr infusions or DFO-DFP combination. Non response being defined as patients who have not achieved an improvement in cardiac MRI T2* of at least 2 ms within the prior year or have had a deterioration in LVEF = 56% in the year prior to study start.
- •Patients with documented liver failure
- •Patients with serum creatinine > ULN or with significant proteinuria as indicated by a urinary protein/creatinine ratio = 1.0 in a non-first void urine sample at baseline.
- •Patients with ALT (SGPT) levels > 5 x ULN.
- •Patients with considerable impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox / ICL670 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection.
- •History or clinical evidence of pancreatic injury or pancreatitis.
- •Patients with a known hypersensitivity to any of the study drugs or the drug’s excipients.
- •History of clinically relevant ocular and/or auditor toxicity related to iron chelation therapy.
- •Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing any of the treatment options or patients unwilling or unable to comply with the protocol.
- •Patients with a known history of HIV seropositivity (Elisa or Western blot).
- •History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
- •Female patients who are pregnant or breast feeding.
- •Female patients of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test = 48 hours prior to the study drugs.
- •Patients participating in another clinical trial or receiving an investigational drug.
- •History of non-compliance with medical regimens or patients who are considered potentially unreliable and/or not cooperative, unwilling or unable to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanomaEUCTR2016-002114-50-SESahlgrenska University Hospital29
进行中（未招募）
不适用
A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma - APO866 for CTCPrimary cutaneous lymphomas are non-Hodgkin lymphomas that present to the skin without evidence of extracutaneous disease at the time of diagnosis. It refers to either to cutaneous T-cell lymphoma (CTCL) or cutaneous B-cell lymphoma (CBCL). The primary cutaneous lymphomas are classified according to the WHO-EORTC classification. CTCL constitutes about 65% of all primary cutaneous lymphomas, of which mycosis fungoides is the most prevalent clinical presentation.MedDRA version: 8.1Level: PTClassification code 10028483EUCTR2005-006157-24-DETopoTarget A/S25
进行中（未招募）
不适用
An multicenter open label phase II study to assess the efficiency and safety of APO866 in the treatment patients with refractory or relapsed cutaneous T-cell lymphoma - APO866 for CTCPrimary cutaneous lymphomas are non-Hodgkin lymphomas that present to the skin without evidence of extracutaneous disease at the time of diagnosis. It refers to either to cutaneous T-cell lymphoma (CTCL) or cutaneous B-cell lymphoma (CBCL). The primary cutaneous lymphomas are classified according to the WHO-EORTC classification. CTCL constitutes about 65% of all primary cutaneous lymphomas, of which mycosis fungoides is the most prevalent clinical presentation.MedDRA version: 8.1Level: PTClassification code 10028483EUCTR2005-006157-24-ATTopoTarget A/S25
进行中（未招募）
不适用
A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells - NDEUCTR2007-002155-17-ITGlaxoSmithKline Research & Development Limited62
进行中（未招募）
1 期
A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cellsAdvanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cellsMedDRA version: 9.1 Level: LLT Classification code 10057654 Term: Breast cancer femaleEUCTR2007-002155-17-GBGlaxoSmithKline Research and Development Limited